SCHEMBL5023341

SCHEMBL5023341

COc1nc(-c2cccc(Cl)c2)c2cc(C(=O)N(C)OC)ccc2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAT2A P31153 1/20 0.56
PRNP P04156 1/20 0.45
CSNK2A2 P19784 1/20 0.41
CSNK2B P67870 1/20 0.41
NR1I3 Q14994 1/20 0.41
HTT P42858 2/20 0.40
ALDH1A1 P00352 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
ALOX12 P18054 1/20 0.40
CYP2C19 P33261 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
GPBAR1 Q8TDU6 1/20 0.38
KDM4E B2RXH2 2/20 0.37
MAPT P10636 2/20 0.37
HPGD P15428 2/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5027009 0.89 ALDH1A1 (0.43) MAT2ACSNK2A2CSNK2BNR1I3HTT
SCHEMBL12590494 0.77 ALDH1A1 (0.47) HTTALDH1A1CYP3A4CYP2C9ALOX12
SCHEMBL3874243 0.75 HSD17B2 (0.48) HTTALDH1A1MAPTHPGDLMNA
SCHEMBL111914 0.72 HPGD (0.51) HTTALDH1A1NPC1RAB9AGPBAR1
SCHEMBL3557898 0.72 HPGD (0.46) MAT2ACSNK2A2CSNK2BNR1I3HTT
SCHEMBL5658696 0.71 MAT2A (0.42) MAT2ACSNK2A2CSNK2BHTTALDH1A1
SCHEMBL5782688 0.69 CSNK2A2 (0.46) MAT2ACSNK2A2CSNK2BGPBAR1KDM4E
SCHEMBL14039064 0.69 CSNK2A2 (0.47) MAT2ACSNK2A2CSNK2BALDH1A1KDM4E
SCHEMBL3553323 0.68 KDM4E (0.55) CSNK2A2CSNK2BHTTALDH1A1KDM4E
SCHEMBL13694026 0.67 MLYCD (0.44) RAB9AKDM4EMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1322650-B1 FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINE AND QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2008-09-24 EP disclosed
US-7196094-B2 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives JANSSEN PHARMACEUTICA, N.V. (BE) 2007-03-27 US disclosed
US-20030207887-A1 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2003-11-06 US disclosed
EP-1322650-A2 FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINE AND QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2003-07-02 EP disclosed
WO-2002024686-A2 FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINE AND QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207887-A1 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives FNTA, FNTB, RCE1 MAT2A 1264/4885PRNP 4857/4885CSNK2A2 1315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.